Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced the signing of a license agreement with Japan-based RIN Institute Inc., granting Mycenax rights to apply RIN’s proprietary Val-Leu-Lys (VLK) linker technology in CDMO services worldwide.
RIN’s VLK linker has demonstrated superior anti-tumour efficacy and high serum stability, enabling the development of advanced ADCs. Specifically, the VLK linker facilitates cytotoxicity through two mechanisms: action within the tumour microenvironment and enhanced ADC internalization. The agreement strengthens Mycenax’s capability to deliver differentiated ADC solutions for global pharmaceutical partners.
“We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions,” said Pei-Jiun Chen, CEO and president of Mycenax. “This collaboration further enhances our technical capabilities and reinforces our commitment to advancing next-generation ADC therapeutics.”
The partnership builds upon the Letter of Intent (LOI) signed on April 7, 2025, which laid the foundation for closer cooperation between the two companies in advancing ADC innovation.
RIN was established in January 2016, for development of anti-cancer antibody drugs both for therapeutic as well as diagnostic uses based upon the research results by Dr. Yasuhiro Matsumura, Director of Research and former Chief of Division of Developmental Therapeutics, EPOC, National Cancer Center (NCC).
Mycenax Biotech Inc. is a leading CDMO in Taiwan offering integrated biologics solutions from cell line development to drug product manufacturing. |